MedTrace Logo

HAIC in Combination with PD-1 Inhibitors and Lenvatinib for Intermediate and Advanced HCC After the Failure of Systemic Therapy Recommended by BCLC

NCT06632093 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 84

Last updated 2024-10-08

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and efficacy of hepatic arterial infusion chemotherapy (HAIC) in combination with PD-1 inhibitors and Lenvatinib in patients with intermediate or advanced-stage hepatocellular carcinoma (HCC) after failure of systemic therapy recommended by BCLC.

Conditions

  • BCLC Stage B Hepatocellular Carcinoma
  • BCLC Stage C Hepatocellular Carcinoma
  • Hepatic Arterial Infusion Chemotherapy
  • Lenvatinib
  • PD-1
  • Systemic Therapy

Interventions

PROCEDURE

hepatic artery infusion chemotherapy

Hepatic arterial infusion chemotherapy including FOLFOX and RALOX

DRUG

Lenvatinib + PD-1 monoclonal antibody

PD-1 inhibitors including Camrelizumab, Sintilimab, Tislelizumab

Sponsors & Collaborators

  • First Hospital of China Medical University

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-09-16
Primary Completion
2025-09-30
Completion
2025-12-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06632093 on ClinicalTrials.gov